NCT03285711

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).

Conditions

• Lupus Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	Filgotinib	200 mg tablet administered orally once daily
DRUG	Lanraplenib	30 mg tablet administered orally once daily
DRUG	Filgotinib placebo	Tablet administered orally once daily
DRUG	Lanraplenib placebo	Tablet administered orally once daily

Timeline

• Start date: 2017-10-06
• Primary completion: 2019-05-03
• Completion: 2020-02-03
• First posted: 2017-09-18
• Last updated: 2020-05-18
• Results posted: 2020-05-18

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study